Announced Fri, 24 Jul · 19:09 IST
MedPlus Q1 FY27 earnings call transcript filed; capex plans put on hold
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹722.00
prior close
₹720.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.0+0.4-0.1——————————
Up moveDown movePending
AI summary
MedPlus Q1 FY27 revenue INR 18,796 million; EBITDA INR 651 million at 3.5% margin. Pharmacy grew 21.8% year-on-year. Net store additions of 146; maintains 800 target for FY27 (total 5,476). Capex plans (food park, wellness) put on hold citing market feedback. Margins pressured by private label mix drop to 20% of sales and labor cost hikes. Diagnostics revenue INR 370.8 million. Promoter pledge debt about INR 1,150 crores.
Likely market impact
Capex reversal may please investors; however margin pressure from mix and labor costs remains. Store growth and revenue strong.